89bio Presents New Analysis of Data from Phase 2 ENTRIGUE
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic
Globe Newswire5-03-2023, 01:31
XPENG Rolls Out XOS 5.2 OTA, Enhancing Global User Experience 19-08-2024, 23:46